Iovance Biotherapeutics (IOVA) Financials: Revenue & Earnings

IOVA price $14.70 +0.12 +0.82%

Ticker
IOVA
Price
$14.70
Change
+0.12 +0.82%
Market cap ?
$6.66B
P/E ?
-18.88
Forward P/E ?
61.00
Dividend yield ?
0.00%
Beta ?
0.76
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
48
Value
44
Quality
46
Growth
54

Stocklytics score rationale: value 44, quality 46, growth 54.

Financials

2016201720182019202020212022202320242025
00000001189000164070000263502000

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary…

Fair value

IOVA fair value $6.64. Price $14.70. Price is 121% above fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 34.54M. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 452.97M. Net debt -114.63M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Model uncertainty high for this stock

Compare IOVA

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-05—-0.08—115.53M
2026-08-06-0.11-0.1399.31M87.83M
2026-05-07-0.19-0.1971.43M77.84M
2026-02-24-0.18-0.2286.71M80.71M
2025-11-06-0.25-0.2967.45M82.17M
2025-08-07-0.33-0.2959.95M78.32M
2025-05-08-0.36-0.2549.32M82.37M
2025-02-27-0.26-0.2673.69M72.17M
2024-11-07-0.28-0.3158.55M71.57M
2024-08-08-0.34-0.3731.11M24.59M
2024-05-09-0.42-0.45715.00K2.07M
2024-02-28-0.45-0.44482.00K1.39M
2023-11-07-0.46-0.46469.00K1.72M
2023-08-08-0.47-0.81238.00K3.58M
2023-05-09-0.50-0.84—200.00K
2023-02-28-0.64-0.64——
2022-11-03-0.63-0.64——
2022-08-04-0.63-0.60——
2022-05-05-0.58-0.64——
2022-02-24-0.63-0.56——
2021-11-04-0.55-0.52——
2021-08-05-0.53-0.52——
2021-05-06-0.51-0.48——
2021-02-25-0.47-0.46——
2020-11-05-0.40-0.46—18.30M
2020-08-06-0.47-0.52—16.19M
2020-05-05-0.55-0.53——
2020-02-25-0.50-0.42——
2019-11-04-0.40-0.40——
2019-08-01-0.38-0.29——
2019-05-07-0.30-0.29——
2019-02-27-0.27-0.27——
2018-11-06-0.36-0.33——
2018-08-06-0.34-0.32——
2018-05-10-0.26-0.29——
2018-03-12-0.32-0.32——
2017-10-31-0.31-0.35——
2017-08-01-0.32-0.35——
2017-05-01-0.33-0.28——
2017-03-07-0.25-0.25——

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-30Berkowitz NoahBuy180.00K——
2026-09-30Berkowitz NoahBuy135.00K$14.822.00M
2026-09-30Berkowitz NoahBuy135.00K——
2026-09-30Berkowitz NoahOther0——
2026-09-08Vogt Frederick GBuy15.63K——
2026-09-08Vogt Frederick GSell6.64K$8.7057.75K
2026-09-08Vogt Frederick GSell15.63K——
2026-09-08BILINSKY IGORBuy7.81K——
2026-09-08BILINSKY IGORSell3.98K$8.7034.59K
2026-09-08BILINSKY IGORSell7.81K——
2026-09-08Puri Raj K.Buy9.77K——
2026-09-08Puri Raj K.Sell4.48K$8.7038.96K
2026-09-08Puri Raj K.Sell9.77K——
2026-09-01Vogt Frederick GBuy41.67K——
2026-09-01Vogt Frederick GSell17.70K$8.28146.57K
2026-09-01Vogt Frederick GSell41.67K——
2026-09-01Puri Raj K.Buy5.47K——
2026-09-01Puri Raj K.Sell2.51K$8.2820.77K
2026-09-01Puri Raj K.Sell5.47K——
2026-09-01BILINSKY IGORBuy8.79K——
2026-09-01BILINSKY IGORSell4.47K$8.2837.03K
2026-09-01BILINSKY IGORSell8.79K——
2026-08-10Kirby Daniel GordonBuy10.00K——
2026-08-10Kirby Daniel GordonSell2.44K$6.4015.59K
2026-08-10Kirby Daniel GordonSell10.00K——
2026-08-06Roche Corleen M.Sell49.99K——
2026-08-06Roche Corleen M.Buy49.99K——
2026-08-06Roche Corleen M.Sell21.24K$6.21131.89K
2026-06-16WEISER MICHAELBuy90.32K——
2026-06-16Dukes Iain D.Buy180.63K——
2026-06-16Countouriotis AthenaBuy90.32K——
2026-06-16Maynard Ryan DBuy90.32K——
2026-06-16Puri Raj K.Buy15.00K——
2026-06-05Vogt Frederick GBuy15.62K——
2026-06-05Vogt Frederick GSell6.64K$4.2328.08K
2026-06-05Vogt Frederick GSell15.62K——
2026-06-05GRAF FINCKENSTEIN FRIEDRICHBuy7.81K——
2026-06-05GRAF FINCKENSTEIN FRIEDRICHSell3.98K$4.2316.82K
2026-06-05GRAF FINCKENSTEIN FRIEDRICHSell7.81K——
2026-06-05Puri Raj K.Buy9.77K——
2026-06-05Puri Raj K.Sell3.84K$4.2316.26K
2026-06-05Puri Raj K.Sell9.77K——
2026-06-05BILINSKY IGORBuy7.81K——
2026-06-05BILINSKY IGORSell3.98K$4.2316.82K
2026-06-05BILINSKY IGORSell7.81K——
2026-06-01Vogt Frederick GBuy41.67K——
2026-06-01Vogt Frederick GSell17.70K$3.9670.10K
2026-06-01Vogt Frederick GSell41.67K——
2026-06-01Puri Raj K.Buy5.47K——
2026-06-01Puri Raj K.Sell2.51K$3.969.93K
2026-06-01Puri Raj K.Sell5.47K——
2026-06-01GRAF FINCKENSTEIN FRIEDRICHBuy8.79K——
2026-06-01GRAF FINCKENSTEIN FRIEDRICHSell4.47K$3.9617.71K
2026-06-01GRAF FINCKENSTEIN FRIEDRICHSell8.79K——
2026-06-01BILINSKY IGORBuy8.79K——
2026-06-01BILINSKY IGORSell4.47K$3.9617.71K
2026-06-01BILINSKY IGORSell8.79K——
2026-05-11Kirby Daniel GordonBuy10.00K——
2026-05-11Kirby Daniel GordonSell2.44K$3.709.01K
2026-05-11Kirby Daniel GordonSell10.00K——
2026-03-09Roche Corleen M.Buy132.20K——
2026-03-09Vogt Frederick GBuy235.00K——
2026-03-09Puri Raj K.Buy117.50K——
2026-03-09GRAF FINCKENSTEIN FRIEDRICHBuy58.75K——
2026-03-09Kirby Daniel GordonBuy132.20K——
2026-03-09BILINSKY IGORBuy117.50K——
2026-03-05Vogt Frederick GBuy62.49K——
2026-03-05Vogt Frederick GSell26.75K$4.58122.54K
2026-03-05Vogt Frederick GSell62.49K——
2026-03-05GRAF FINCKENSTEIN FRIEDRICHBuy31.25K——
2026-03-05GRAF FINCKENSTEIN FRIEDRICHSell16.52K$4.5875.66K
2026-03-05GRAF FINCKENSTEIN FRIEDRICHSell31.25K——
2026-03-05Puri Raj K.Buy39.06K——
2026-03-05Puri Raj K.Sell18.36K$4.5884.09K
2026-03-05Puri Raj K.Sell39.06K——
2026-03-05BILINSKY IGORBuy31.25K——
2026-03-05BILINSKY IGORSell16.63K$4.5876.16K
2026-03-05BILINSKY IGORSell31.25K——
2026-03-02Vogt Frederick GBuy52.09K——
2026-03-02Vogt Frederick GSell22.81K$3.7986.45K
2026-03-02Vogt Frederick GSell41.67K——
2026-03-02Vogt Frederick GSell10.42K——
2026-03-02BILINSKY IGORBuy12.31K——
2026-03-02BILINSKY IGORSell6.90K$3.7926.16K
2026-03-02BILINSKY IGORSell8.79K——
2026-03-02BILINSKY IGORSell3.52K——
2026-03-02Puri Raj K.Buy5.47K——
2026-03-02Puri Raj K.Sell2.80K$3.7910.60K
2026-03-02Puri Raj K.Sell5.47K——
2026-03-02GRAF FINCKENSTEIN FRIEDRICHBuy12.70K——
2026-03-02GRAF FINCKENSTEIN FRIEDRICHSell7.12K$3.7926.99K
2026-03-02GRAF FINCKENSTEIN FRIEDRICHSell8.79K——
2026-03-02GRAF FINCKENSTEIN FRIEDRICHSell3.91K——
2026-02-24Kirby Daniel GordonBuy120.00K——
2026-02-24Kirby Daniel GordonSell34.16K$3.78129.14K
2026-02-24Kirby Daniel GordonSell150.00K——
2026-02-10Kirby Daniel GordonSell40.00K——
2026-02-10Kirby Daniel GordonBuy40.00K——
2026-02-10Kirby Daniel GordonSell16.45K$2.6042.77K
2025-12-02GRAF FINCKENSTEIN FRIEDRICHBuy3.91K——

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 305, holders +3 vs prior quarter. Ownership 64.37%.

HolderSharesChangeChange %Value
BLACKROCK, INC.36.96M5.88M+18.91%153.74M
MHR FUND MANAGEMENT LLC28.97M00.00%120.50M
STATE STREET CORP24.48M7.03M+40.29%101.83M
TWO SIGMA INVESTMENTS, LP19.01M5.32M+38.89%79.08M
VANGUARD CAPITAL MANAGEMENT LLC18.20M1.59M+9.55%75.73M
VANGUARD PORTFOLIO MANAGEMENT LLC14.39M2.69M+22.97%59.86M
GEODE CAPITAL MANAGEMENT, LLC10.32M1.75M+20.44%42.96M
MILLENNIUM MANAGEMENT LLC8.53M-888.37K-9.44%35.47M
DIMENSIONAL FUND ADVISORS LP6.46M3.81M+144.19%26.88M
PALO ALTO INVESTORS LP5.30M-1.05M-16.59%22.03M
GOLDMAN SACHS GROUP INC5.10M-3.66M-41.82%21.20M
NUVEEN, LLC5.00M1.33M+36.37%20.79M
BANK OF AMERICA CORP /DE/4.99M-3.50M-41.18%20.77M
MORGAN STANLEY4.99M-1.21M-19.59%20.74M
JUPITER ASSET MANAGEMENT LTD4.54M4.54MNew18.87M
JANE STREET GROUP, LLC4.39M4.17M+1833.06%18.28M
NORTHERN TRUST CORP4.15M1.28M+44.47%17.28M
AQR CAPITAL MANAGEMENT LLC3.87M3.25M+519.96%16.10M
WELLS FARGO & COMPANY/MN3.25M1.18M+56.72%13.51M
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.3.22M3.22MNew13.39M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC3.22M435.93K+15.66%13.39M
HRT FINANCIAL LP3.10M-388.51K-11.14%12.89M
SUSQUEHANNA INTERNATIONAL GROUP, LLP2.67M958.50K+56.08%11.10M
SUSQUEHANNA INTERNATIONAL GROUP, LLP2.66M947.64K+55.45%11.05M
VANGUARD FIDUCIARY TRUST CO2.54M358.58K+16.42%10.58M

Earnings and financials

Iovance Biotherapeutics, Inc. (IOVA) trades at $14.70, with a market cap of $6.66B and a trailing P/E of -18.88. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
00000001189000164070000263502000

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Iovance Biotherapeutics (IOVA) Financials: Revenue & Earnings

IOVA$14.70+0.12 +0.82%

$6.66B

Market Cap

-18.88

P/E

61.00

Forward P/E

48

Score

Price History